Lilly to Invest US$6.5 Billion to Build State-of-the-Art Active Pharmaceutical Ingredient Manufacturing Facility in Texas
Introduction:
Eli Lilly and Company has announced plans to invest US$6.5 billion to build a new state-of-the-art manufacturing facility at Generation Park in Houston, Texas, USA.
Features:
The new facility is designed to strengthen domestic manufacturing capacity and support the large-scale production of active pharmaceutical ingredients (APIs) for small molecule medicines.
The site will integrate advanced process technologies, digital automation, and data analytics to improve efficiency, scalability, and product consistency.
Production will include small molecule APIs used across therapeutic areas such as cardiometabolic disorders, oncology, immunology, and neuroscience.
The facility will also focus on manufacturing orforglipron, a small molecule GLP-1 receptor agonist intended for the treatment of metabolic health conditions.
The Texas site forms part of a wider expansion programme involving four new manufacturing facilities across the United States, aimed at enhancing supply resilience and supporting future medicine pipelines.
Construction will follow sustainability principles, incorporating resource-efficient systems and environmentally responsible design features to reduce energy consumption and minimise environmental impact.
The facility is expected to become operational within five years and will serve as a key hub supporting continuous innovation and production reliability.
Specifications:
| Name | Eli Lilly and Company |
| Type | New Construction |
| Budget | US$6.5 billion |
| Year | 2029 |
